Arrowhead Pharmaceuticals Inc
Company Profile
Business description
Arrowhead Pharmaceuticals Inc develops medicines using its targeted RNAi molecule, TRiM, platform that uses a natural pathway to silence genes causing disease. It has commercialized Redemplo (plozasiran) as an adjunct to diet to reduce triglycerides (TGs) in adults with Familial Chylomicronemia Syndrome (FCS). Redemplo has received marketing authorization for FCS across the European Union, the USA, Canada, Australia, China, and the United Kingdom. It has several drug candidates in clinical trials ranging from early to late stage, including both partnered and wholly-owned candidates such as Zodasiran, Olpasiran, Fazirsiran, ARO-C3, and others being developed as therapies for various cardiometabolic, pulmonary, liver, neuromuscular, and other conditions. It operates as a single segment.
Contact
177 E Colorado Boulevard
Suite 700
PasadenaCA91105
USAT: +1 626 304-3400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2027
Employees
711
Stocks News & Analysis
stocks
Overvalued ASX share has overly ambitious profit target
stocks
7 undervalued US stocks that crushed earnings
stocks
Undervalued ASX share hitting on all cylinders
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,997.30 | 168.10 | -1.83% |
| CAC 40 | 8,246.31 | 105.69 | -1.27% |
| DAX 40 | 26,266.46 | 332.18 | -1.25% |
| Dow JONES (US) | 51,608.17 | 739.38 | -1.41% |
| FTSE 100 | 10,744.36 | 137.19 | -1.26% |
| HKSE | 23,508.17 | 245.67 | -1.03% |
| NASDAQ | 24,509.76 | 626.52 | -2.49% |
| Nikkei 225 | 58,860.43 | 801.59 | -1.34% |
| NZX 50 Index | 14,306.96 | 3.19 | 0.02% |
| S&P 500 | 7,416.59 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,883.20 | 161.50 | -1.79% |
| SSE Composite Index | 3,584.58 | 17.99 | -0.50% |